Sarepta Therapeutics (SRPT) Tops Q4 EPS by 4c, Beats on Revenues

Note: EPS may not be comparable

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.28), $0.04 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.48 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• Morgan Stanley upgrades CDW on stronger AI-driven server demand